• Education
  • Points
  •  Download App
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates

Other Services
 Education
 Points
  Download App
Country
singapore
malaysia
indonesia
thailand
philippines
vietnam
india
australia
korea
new zealand
Account
The MIMS logo.
  1. Diseases
  2. Depression
  3. ...
    • Diseases
    • Depression
  4. Follow Up

Depression Follow Up

Last updated: 01 July 2025
Reviewed by
Advisory--Board/Special--CharacterTest!@#$$%^&*()PAGINATION TESTMIMS Psychiatry Honorary Editorial Advisory Board
Follow Up
Monitoring
OverviewHistory and Physical ExaminationDiagnosisManagement
IntroductionEpidemiologyPathophysiologyRisk Factors
Clinical PresentationHistoryDiagnosis or Diagnostic Criteria
Differential Diagnosis
Principles of TherapyPharmacological therapyNonpharmacological
Monitoring
Dopamine-Norepinephrine Reuptake Inhibitor*Melatonergic Agonist*Monoamine Oxidase Inhibitors (MAOIs)*Multimodal Serotonin Modulator*Noradrenergic & Specific Serotonergic Antidepressant (NaSSA)*Noradrenaline Reuptake Inhibitor*Other Agent*Selective Serotonin Reuptake Enhancer (SSRE)*Selective Serotonin Reuptake Inhibitors (SSRIs)*Serotonin & Norepinephrine Reuptake Inhibitors (SNRIs)*Serotonin Modulators*Tetracyclic Antidepressants*Tricyclic Antidepressants (TCAs)*Other AntidepressantAtypical/2nd Generation AntipsychoticsLithiumOther AntipsychoticsRelated MIMS Drugs
OverviewHistory and Physical ExaminationDiagnosisManagement
IntroductionEpidemiologyPathophysiologyRisk Factors
Clinical PresentationHistoryDiagnosis or Diagnostic Criteria
Differential Diagnosis
Principles of TherapyPharmacological therapyNonpharmacological
Monitoring
Dopamine-Norepinephrine Reuptake Inhibitor*Melatonergic Agonist*Monoamine Oxidase Inhibitors (MAOIs)*Multimodal Serotonin Modulator*Noradrenergic & Specific Serotonergic Antidepressant (NaSSA)*Noradrenaline Reuptake Inhibitor*Other Agent*Selective Serotonin Reuptake Enhancer (SSRE)*Selective Serotonin Reuptake Inhibitors (SSRIs)*Serotonin & Norepinephrine Reuptake Inhibitors (SNRIs)*Serotonin Modulators*Tetracyclic Antidepressants*Tricyclic Antidepressants (TCAs)*Other AntidepressantAtypical/2nd Generation AntipsychoticsLithiumOther AntipsychoticsRelated MIMS Drugs

Monitoring

Provide frequent follow-up during the first 2-4 months of therapy until remission occurs (acute phase). Monitor patients for adverse drug effects and response to therapy. Assess the degree of danger to self or others. It is important to monitor symptomatic and functional status of the individual, and to watch out for any switch to mania. Lastly, reassess therapy after 4-8 weeks.

The MIMS logo.
  • Drugs
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • MIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Points
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with MIMS
A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
MIMS Specialty v3.9.0
Copyright © 2025 MIMS Pte Ltd. All rights reserved. STG
MIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.